Abstract
There are few data on the real-world effectiveness of COVID-19 vaccines and boosting in Africa, which experienced widespread SARS-CoV-2 infection before vaccine availability. We assessed the association between vaccination and severe COVID-19 in the Western Cape, South Africa, in an observational cohort study of >2 million adults during 2020–2022. We described SARS-CoV-2 testing, COVID-19 outcomes, and vaccine uptake over time. We used multivariable cox models to estimate the association of BNT162b2 and Ad26.COV2.S vaccination with COVID-19-related hospitalization and death, adjusting for demographic characteristics, underlying health conditions, socioeconomic status proxies, and healthcare utilization. We found that by the end of 2022, 41% of surviving adults had completed vaccination and 8% had received a booster dose. Recent vaccination was associated with notable reductions in severe COVID-19 during periods dominated by Delta, and Omicron BA.1/2 and BA.4/5 (sub)lineages. During the latest Omicron BA.4/5 wave, within 3 months of vaccination or boosting, BNT162b2 and Ad26.COV2.S were each 84% effective against death (95% CIs: 57–94 and 49–95, respectively). However, distinct reductions of effectiveness occurred at longer times post completing or boosting vaccination. Results highlight the importance of continued emphasis on COVID-19 vaccination and boosting for those at high risk of severe COVID-19, even in settings with widespread infection-induced immunity.
All Related Versions
Funding Information
  • Western Cape Department of Health and Wellness for the Western Cape Provincial Health Data Centre (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
  • US National Institutes for Health (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
  • United States Agency for International Development (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
  • Bill and Melinda Gates Foundation (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
  • European Commission (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
  • Grand Challenges ICODA pilot initiative delivered by Health Data Research UK and funded by the Bill & Melinda Gates and Minderoo Foundations (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
  • Wellcome Trust (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)
  • Bill and Melinda Gates Foundation (R01 HD080465, U01 AI069924, 72067418CA00023, 1164272, 1191327, 101045989, INV-017293, 203135/Z/16/Z, 222574)

This publication has 30 references indexed in Scilit: